Golan Bitton - D Pharm CEO, Director

DPRM -- Israel Stock  

ILS 430.00  0.60  0.14%

  CEO
Mr. Golan Bitton was appointed Chief Executive Officer and Director at D Pharm Ltd effective September 6, 2018. His work experience includes the following roles Governmental Employee and Chief Executive Officer and Director at UNV Medicine Ltd . He holds a Bachelors degree in Economics and Management from Max Stern Academic College of Emek Yezreel.
Age: 41  CEO Since 2018      
972 8 938 5100  http://www.dpharm.com

Management Efficiency

The company has return on total asset (ROA) of (42.09) % which means that it has lost $42.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (400.0) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 317K in total debt with debt to equity ratio (D/E) of 45.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. D Pharm LTD has Current Ratio of 1.51 which is within standard range for the sector.

Similar Executives

Found 6 records

CEO Since

Itzhak IsraelKitov Pharma Ltd
2012
Menachem CohenMedivie Therapeutic Ltd
2017
Yuval BernshteinSolegreen Ltd
2018
Itai HechtMedivie Therapeutic Ltd
2018
Tom ShafranSolegreen Ltd
2018
Gil EfronKitov Pharma Ltd
2018

Entity Summary

D-Pharm LTD., a drug-development company, focuses on the development of drugs for the treatment of central nervous system conditions. D-Pharm LTD. was founded in 1993 and is based in Rehovot, Israel. D Pharm operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.D Pharm LTD (DPRM) is traded on Tel Aviv Stock Exchange in Israel and employs 11 people.

D Pharm LTD Leadership Team

Emanuel Kahane, IR Contact Officer
Tamar Kfir, Director
Ofir Shachaf, Director
Irit Kaufman, Independent Director
David Grossman, Chairman of the Board
Itschak Shrem, Chairman of the Board
Aharon Schwartz, Executive Chairman of the Board
Golan Bitton, CEO, Director
Ronen Rosenbloom, Director
Nir Zvi, Director
Ofra Yamin, VP of Fin. and HR
Yaron Meyer, General Counsel, Secretary
Assaf Segal, Director
Ofer Gonen, Director
Joshua Levine, Director
Anat Benish, External Director
Sagi Tamir, External Director
Yossi Hatan, Vice President - Finance
Gilad Rosenberg, Vice President Clinical Development
Sigal Gefen, External Director
Eli Cohen, Director
Alexander Kozak, Co-Founder, CEO and Pres
Zohara Ran, Independent Director

Stock Performance Indicators

Did you try this?

Run Risk-Return Analysis Now

   

Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
All  Next Launch Module

D Pharm Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for D Pharm and Kitov Pharma. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.
Search macroaxis.com